All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-11T16:55:47.000Z

AACR 2017 | Poster 4295/4 – AZ’5576 demonstrates in vitro and in vivo activity in preclinical models of ABC Diffuse Large B-Cell Lymphoma

Apr 11, 2017
Share:

Bookmark this article

At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Cell Death in Cancer” took place.

One of the posters on display (4295 / 4) was titled “AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in vivo activity in diverse preclinical models of non-Hodgkin lymphoma” by Justin Cidado from AstraZeneca, Waltham, MA, and colleagues.

AZ’5576 is an oral, highly selective inhibitor of CDK9. Using cell potency and magnitude of caspase activation to define sensitivity, the group previously found that AZ’5576 shows broad in vitro and in vivo activity in Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). The data presented includes their expanded scope encompassing Non-Hodgkin Lymphomas (NHLs).

Key Highlights:

  • In vitro screening assays found approximately half (19/35) of NHL cell lines undergo cell death in response to AZ’5576, demonstrating a potency <520nM and a maximum caspase activation >55% after 6 hours of treatment
  • Combining AZ’5576 with acalabrutinib (BTK inhibitor) enhanced cell death versus that observed with either agent alone in BTK inhibitor-sensitive ABC-DLBCL cell lines
  • In a mouse xenograft model of ABC-DLBCL cell line OCILY10, significant anti-tumor activity was associated with rapid reduction of pSer2-RNAPII levels, loss of MCL-1 and MYC, after intermittent dosing of AZ’5576
  • In the OCILY10 xenograft model, AZ’5576 plus acalabrutinib in vivo drove tumors into regression (Tumor Growth Inhibition [TGI] with combination = 199%) compared to partial TGI from either single agent (AZ’5576 TGI =79%; acalabrutinib TGI = 58%)
  • In aggressive Eµ-Myc transgenic mouse model of B-Cell Lymphoma, administration of AZ’5576 resulted in a >50-day increase in median overall survival in vivo

The poster was concluded by stating that these data indicate that inhibition of CDK9 has therapeutic potential in NHL, either as monotherapy or in combination with BTK inhibition.

  1. Cidado J. et al. AZ’5576, a selective CDK9 inhibitor, demonstrates in vitro and in vivo activity in diverse preclinical models of non-Hodgkin lymphoma [Poster]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [4295 / 4].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox